Slingshot Insights

Catalyst

Slingshot members are tracking this event:

FDA Grants Conatus Fast Track Designation for Development of Emricasan in liver cirrhosis caused by NASH

Source Link:: http://ir.conatuspharma.com/releasedetail.cfm?ReleaseID=953084

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CNAT

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations.

http://ir.conatuspha...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 03, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Fast Track Designation, Emricasan, Nash, Cirrhosis, Liver Disease, Nash Fibrosis